Intellia Therapeutics (NTLA) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Intellia Therapeutics is the larger company by market cap ($1.84 billion vs $2.5 million), about 726.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTLA | VRAX |
|---|---|---|
| Share price | $13.10 | $1.88 |
| Market cap | $1.84B | $2.53M |
| 1-day change | +3.97% | -5.53% |
| YTD return | +40.16% | — |
| 1-year return | -48.51% | — |
| 5-year return | -90.34% | — |
| EPS (TTM) | $-3.35 | $-12.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $67.67M | — |
| Revenue growth (YoY) | +16.92% | — |
| Net income (latest FY) | $-412.69M | — |
| Operating margin | -651.67% | — |
| Net margin | -609.85% | — |
| 52-week high | $28.25 | $21.75 |
| 52-week low | $7.95 | $1.81 |
| Distance from 52-week high | -53.63% | -91.36% |
| Analyst consensus | buy | — |
| Avg. price target upside | +76.41% | — |
| Average volume | 4.26M | 650.11K |
| Shares outstanding | 140.13M | 1.34M |
| Employees | 377 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Intellia Therapeutics is about 726.0 times larger than Virax Biolabs Group by market value ($1.84B vs $2.53M).
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
About Virax Biolabs Group
VRAX stock →Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 26 employees
NTLA vs VRAX FAQ
Which is bigger, Intellia Therapeutics or Virax Biolabs Group?
Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.84B compared with $2.53M for Virax Biolabs Group (VRAX).
Are Intellia Therapeutics and Virax Biolabs Group in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.